Behavioral and pharmacological validation of the gerbil forced-swim test: Effects of neurokinin-1 receptor antagonists

Neuropsychopharmacology

Volumn 33, Issue 8, 2008, Pages 1919-1928

  Wallace Boone, Tanya L ^a,b   Newton, Amy E ^a   Wright, Robert N ^a   Lodge, Nicholas J ^a   McElroy, John F ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b Roche Palo Alto   (United States)

Author keywords

Antidepressant; Behavioral model; Depression; Forced swim; Gerbil; Neurokinin

Indexed keywords

3 (2 METHOXY 5 TRIFLUOROMETHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 3 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 2 PHENYLPIPERIDINE; AMPHETAMINE; APREPITANT; BENZODIAZEPINE; BUSPIRONE; DESIPRAMINE; FLUOXETINE; HALOPERIDOL; NEFAZODONE; NEUROKININ 1 RECEPTOR ANTAGONIST; PAROXETINE; TRANYLCYPROMINE;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIORAL SCIENCE; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; FEMALE; FORCED SWIMMING TEST; GERBIL; HYPERACTIVITY; IMMOBILIZATION; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; VALIDATION STUDY;

ADRENERGIC UPTAKE INHIBITORS; AMPHETAMINE; ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIPSYCHOTIC AGENTS; BODY WEIGHT; CENTRAL NERVOUS SYSTEM STIMULANTS; DATA INTERPRETATION, STATISTICAL; DEPRESSIVE DISORDER; FEMALE; GERBILLINAE; MALE; MOTOR ACTIVITY; RECEPTORS, NEUROKININ-1; REPRODUCIBILITY OF RESULTS; SEROTONIN UPTAKE INHIBITORS; SEX CHARACTERISTICS; SWIMMING;

EID: 45149083874     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301586     Document Type: Article

References (40)

1. Alonso SJ, Castellano MA, Afonso D, Rodriguez M (1991). Sex differences in behavioral despair: relationships between behavioral despair and open field activity. Physiol Behav 49: 69-72.
2. Ballard TM, Sangar S, Higgins GA (2001). Inhibition of shock-induced foot tapping behaviour in there gerbil by a tachykinin NK1 receptor antagonist. Eur J Pharmacol 412: 255-264.
3. Barros HMT, Ferigolo M (1998). Ethopharmacology of imipramine in the forced-swimming test: gender differences. Neurosci Biobehav Rev 23: 279-286.
4. Beresford IJ, Birch PJ, Hagan RM, Ireland SJ (1991). Investigation into species variants in tachykinin NK1 receptors by use of the non-peptide antagonist, CP-96, 345. Br J Pharmacol 104: 292-293.
5. Bianchi M, Moser C, Lazzarani C, Vecchiato E (2002). Forced swimming test and fluoxetine treatment: in vivo evidence that peripheral 5-HT in rat platelet-rich plasma mirrors cerebral extracellular 5-HT levels, whilst 5-HT in isolated platelets mirrors neuronal 5-HT changes. Exp Brain Res 143: 191-197.
6. Borsini F, Meli A (1988). Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology 94: 147-160.
7. Brotto LA, Barr AM, Gorzalka BB (2000). Sex differences in forced-swum and open-field test behaviours after chronic administration of melatonin. Eur J Pharmacol 402: 87-93.
8. Costall B, Naylor RJ (1975). Detection of the neuroleptic properties of clozapine, sulpiride and thioridazine. Psychopharmacologia 43: 69-74.
9. Crowley JJ, Jones MD, O'Leary OF, Lucki I (2004). Automated tests for measuring the effects of antidepressants in mice. Pharmacol Biochem Behav 78: 269-274.
10. Cryan JF, Markou A, Lucki I (2002). Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 23: 238-245.
11. Detke MJ, Johnson J, Lucki I (1997). Acute and chronic antidepressant drug treatment in the rat forced swimming test model of depression. Exp Clin Psychopharmacol 5: 107-112.
12. Detke MJ, Rickels M, Lucki I (1995). Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology 121: 66-72.
13. Duffy RA, Varty GB, Morgan CA, Lachowicz JE (2002). Correlation of neurokinin (NK) 1 receptor occupancy in gerbil striatum with behavioral effects of NK1 antagonists. J Pharmacol Exp Ther 301: 536-542.
14. File SE, Cheeta S, Akanezi C (2001). Diazepam and nicotine increase social interaction in gerbils: a test for anxiolytic action. Brain Res 888: 311-313.
15. Gentsch C, Cutler M, Vassout A, Veenstra S, Brugger F (2002). Anxiolytic effect of NKP608, a NK1-receptor antagonist, in the social investigation test in gerbils. Behav Brain Res 133: 363-368.
16. Gitter BD, Waters DC, Bruns RF, Mason NR, Nixon JA, Howbert JJ (1991). Species differences in affinities of non-peptide antagonists for substance P receptors. Eur J Pharmacol 197: 237-238.
17. Karolewicz B, Paul IA (2001). Group housing of mice increases immobility and antidepressant sensitivity in the forced swim and tail suspension tests. Eur J Pharmacol 415: 197-201.
18. Keller M, Montgomery S, Ball W, Morrison M, Snavely D, Liu G et al (2006). Lack of efficacy of the substance P (neurokinin 1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry 59: 216-223.
19. Kennett GA, Chaouloff F, Marcou M, Curzon G (1986). Female rats are more vulnerable than males in an animal model of depression: the possible role of serotonin. Brain Res 382: 416-421.
20. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ et al (1998). Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281: 1640-1645.
21. Lucki I (1997). The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol 8: 523-532.
22. Lucki I, Dalvi A, Mayorga AJ (2001). Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology 155: 315-322.
23. Maier SF, Seligman MEP (1976). Learned helplessness: theory and evidence. J Exp Psychol 105: 3-46.
24. Nestler EJ, Gould E, Manji H, Duman RS, Greshenfeld HK, Hen R et al (2002). Preclinical models: status of basic research in depression. Biol Psychiatry 52: 503-528.
25. Page ME, Detke MJ, Dalvi A, Kirby LG, Lucki I (1999). Serotonergic mediation of the effects of fluoxetine, but not desipramine, in the rat forced swimming test. Psychopharmacology 147: 162-167.
26. Porsolt RD, Anton G, Blavet N, Jalfre M (1978a). Behavioural despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 47: 379-391.
27. Porsolt RD, Bertin A, Jalfre M (1977b). Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229: 327-336.
28. Porsolt RD, Bertin A, Jalfre M (1978b). 'Behavioural despair' in rats and mice: strain differences and the effects of imipramine. Eur J Pharmacol 51: 291-294.
29. Porsolt RD, Pichon ML, Jalfre M (1977a). Depression: a new animal model sensitive to antidepressant treatments. Nature 266: 730-732.
30. Rupniak NMJ, Carlson EJ, Webb JK, Harrison T, Porsolt RD, Roux S et al (2001). Comparison of the phenotype of NK1R-/- mice with pharmacological blockade of the substance P (NK1) receptor in assays for antidepressant and anxiolytic drugs. Behav Pharmacol 12: 497-508.
31. Rupniak NMJ, Webb JK, Fisher A, Smith D, Boyce S (2003). The substance P (NK1) receptor antagonist L-760735 inhibits fear conditioning in gerbils. Neuropharmacology 44: 516-523.
32. Santarelli L, Gobbi G, Debs PC, Sibille EL, Blier P, Hen R et al (2001). Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. Proc Natl Acad Sci USA 98: 1912-1917.
33. Steru L, Chermat R, Thierry B, Simon P (1985). The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology 85: 367-370.
34. Sunal R, Grumusel B, Kayaalp SO (1994). Effect of changes in swimming area on results of 'behavioral despair test'. Pharmacol Biochem Behav 49: 891-896.
35. Varty GB, Cohen-Williams ME, Hunter JC (2003). The antidepressant-like effects of neurokinin NK1 receptor antagonists in a gerbil tail suspension test. Behav Pharmacol 14: 87-95.
36. Varty GB, Cohen-Williams ME, Morgan CA, Pylak U, Duffy RA, Lachowicz JE et al (2002b). The gerbil elevated plus-maze II: anxiolytic-like effects of selective neurokinin NK1 receptor antagonists. Neuropsychopharmacology 27: 371-379.
37. Varty GB, Morgan CA, Cohen-Williams ME, Coffin VL, Carey GJ (2002a). The gerbil elevated plus-maze I: behavioral characterization and pharmacological validation. Neuropsychopharmacology 27: 357-370.
38. Wieland S, Lucki I (1990). Antidepressant-like activity of 5-HT1A agonists measured with the forced swim test. Psychopharmacology 101: 497-504.
39. Wong ML, Licinio J (2004). From monoamines to genomic targets: a paradigm shift for drug discovery in depression. Nat Rev Drug Discov 3: 136-151.
40. Zetler G, Baumann GH (1985). Pharmacokinetics and effects of haloperidol in the isolated mouse. Pharmacology 31: 318-327.